Roth Capital Issues Negative Outlook for TRDA Earnings

Key Points

• Roth Capital has revised its Q3 2025 earnings estimate for Entrada Therapeutics, anticipating a loss of ($1.13) per share, down from a prior estimate of ($0.97).
• Wall Street Zen downgraded Entrada Therapeutics from a "hold" rating to a "sell" rating, while HC Wainwright maintained a "buy" rating with a price target of $20.00.
• In its latest quarterly earnings, Entrada reported a loss of ($1.04) per share, which missed the consensus estimate by ($0.18), alongside revenues of just $1.98 million compared to expected $8.17 million.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Equities researchers at Roth Capital decreased their Q3 2025 earnings estimates for Entrada Therapeutics in a research report issued to clients and investors on Wednesday, August 6th. Roth Capital analyst B. Pachaiyappan now expects that the company will post earnings per share of ($1.13) for the quarter, down from their previous estimate of ($0.97). The consensus estimate for Entrada Therapeutics' current full-year earnings is $1.12 per share. Roth Capital also issued estimates for Entrada Therapeutics' Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($3.86) EPS, Q1 2026 earnings at ($1.32) EPS, Q2 2026 earnings at ($1.38) EPS, Q3 2026 earnings at ($1.45) EPS, Q4 2026 earnings at ($1.51) EPS and FY2026 earnings at ($5.66) EPS.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.18). Entrada Therapeutics had a negative return on equity of 17.81% and a negative net margin of 92.30%. The company had revenue of $1.98 million for the quarter, compared to the consensus estimate of $8.17 million.

A number of other equities research analysts have also recently weighed in on the company. Wall Street Zen cut Entrada Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Tuesday, May 20th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $25.67.

Entrada Therapeutics Trading Down 3.3%

NASDAQ TRDA traded down $0.17 during trading hours on Monday, reaching $5.02. The company's stock had a trading volume of 242,106 shares, compared to its average volume of 217,327. The business has a 50-day simple moving average of $6.84 and a 200 day simple moving average of $8.91. Entrada Therapeutics has a 52 week low of $4.93 and a 52 week high of $21.79. The stock has a market cap of $190.96 million, a PE ratio of -2.82 and a beta of -0.12.

Insider Activity at Entrada Therapeutics

In related news, Director Kush Parmar sold 27,000 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total transaction of $202,500.00. Following the sale, the director owned 1,093,313 shares of the company's stock, valued at $8,199,847.50. The trade was a 2.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ventures V. L.P. 5Am sold 6,935 shares of the company's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $7.50, for a total value of $52,012.50. Following the completion of the transaction, the insider directly owned 1,093,313 shares in the company, valued at $8,199,847.50. This represents a 0.63% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 254,000 shares of company stock worth $1,782,000. 7.59% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TRDA. KLP Kapitalforvaltning AS bought a new position in shares of Entrada Therapeutics in the fourth quarter valued at $36,000. BNP Paribas Financial Markets bought a new position in shares of Entrada Therapeutics in the fourth quarter valued at $57,000. Virtus ETF Advisers LLC bought a new position in shares of Entrada Therapeutics in the fourth quarter valued at $68,000. Russell Investments Group Ltd. increased its holdings in shares of Entrada Therapeutics by 53,455.6% in the fourth quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company's stock valued at $83,000 after buying an additional 4,811 shares in the last quarter. Finally, Trexquant Investment LP bought a new position in shares of Entrada Therapeutics in the first quarter valued at $101,000. Institutional investors own 86.39% of the company's stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.